Intellia Therapeutics has received full clearance from the U.S. Food and Drug Administration (FDA) to resume its pivotal Phase 3 clinical trial, known as MAGNITUDE. The decision lifts a complete clinical hold that had been in place, allowing the company to restart patient recruitment for its gene therapy candidate, nex-z. This development marks a significant resolution to a period of regulatory uncertainty that lasted for several months.
Analyst Upgrades Follow Regulatory Green Light
The market response to the FDA’s decision was swift and positive. Analysts at Jones Trading upgraded their rating on Intellia Therapeutics shares from “Hold” to “Buy,” establishing a price target of $29.00. In a similar move, HC Wainwright & Co. reaffirmed its “Buy” recommendation and increased its price target from $25.00 to $30.00. Market experts view the removal of this regulatory overhang as a primary catalyst for the stock’s performance in the near term.
Safety Review and Protocol Revisions
The clinical hold was initially imposed in October 2025 following a serious adverse event. A patient involved in the study developed severe liver complications and subsequently passed away in November of that year. A subsequent autopsy, however, determined the cause of death to be septic shock resulting from a perforated ulcer—an infection deemed unrelated to the investigational therapy.
Should investors sell immediately? Or is it worth buying Intellia Therapeutics?
To secure the trial’s resumption, Intellia has agreed to implement enhanced safety protocols. These revisions include more frequent monitoring of liver function and the introduction of stricter exclusion criteria for potential participants with specific pre-existing medical conditions.
Pipeline Advancements and Financial Runway
Beyond the MAGNITUDE trial, Intellia is progressing another key program targeting hereditary angioedema (HAE). Recent data for its therapy, lonvo-z, continues to demonstrate strong efficacy. One analysis showed that 86% of patients remained attack-free for over six months following a single dose. The company intends to submit a Biologics License Application (BLA) in the United States in the second half of 2026, potentially leading to a commercial launch in 2027.
Financially, Intellia management estimates its annual cash burn for ongoing operations to be approximately $400 million. The next critical milestone for the HAE program is expected in mid-2026, with results from the Phase 3 HAELO study, which will form the foundation for the planned regulatory submission.
Ad
Intellia Therapeutics Stock: Buy or Sell?! New Intellia Therapeutics Analysis from March 6 delivers the answer:
The latest Intellia Therapeutics figures speak for themselves: Urgent action needed for Intellia Therapeutics investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 6.
Intellia Therapeutics: Buy or sell? Read more here...
